Thalassemia Market Size Worth $3.53 Billion by 2022 | CAGR: 10.8%: Grand View Research, Inc.

Thursday, April 12, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, April 12, 2018 /PRNewswire/ --

The global thalassemia market size is expected to be valued

at USD 3.53 billion by 2022, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 10.8% during the forecast period. Increase in demand for a universal cure, rise in awareness about the disease, and technological
advancements are likely to increase the adoption of gene therapies. 

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in U.S.

Increase in incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Browse full research report with TOC on "Thalassemia Market Size, Share & Trends Analysis Report By Therapeutic Class (Iron Chelating Drugs), By Pipeline (Gene Therapy), By Region (U.S., U.K., France, Germany, Italy, Spain, Japan), And Segment Forecasts, 2016 - 2022" at: https://www.grandviewresearch.com/industry-analysis/thalassemia-market

Further Key Findings From the Report Suggest: 

  • The global thalassemia market is expected to expand at a lucrative CAGR of 10.8% over the forecast period because of improved safety and efficacy profiles of gene therapy
  • India and Thailand are expected to offer lucrative growth opportunities for market expansion
  • Some of the key players in the industry with promising pipeline products are bluebird bio, Inc.; Acceleron Pharma; Novartis AG; Incyte Corporation; Kiadis Pharma; Gamida Cell; and Celgene Corporation
  • Blood transfusion and iron chelation therapies were the preferred treatment options for thalassemia in 2016, owing to their higher usage, ease, and affordability. However, the segments are likely to lose market share over the forecast period due to increase in adoption of curative gene therapy
  • Regionally, among the seven major markets, EU5 held the dominant share in terms of revenue in 2016, followed by U.S. and Japan
  • U.S. is expected to be the fastest growing region with a lucrative CAGR from 2016 to 2022 due to increase in prevalence of the disease and presence of well-established healthcare services

Browse related reports by Grand View Research: 

  • Anti-Tumor Drugs Market - The global market for anti-tumor drugs is expected to surpass USD 110 billion by 2022, growing at a CAGR greater than 6% over the forecast period.
  • Arthroscopy Market - The Arthroscopy market was valued at USD 4.0 billion in 2015 and is expected to witness a CAGR of 4.9% over the forecast period.
  • Anti-Obesity Therapeutics Market - The Global anti-obesity therapeutics market is forecasted to grow at a CAGR of above 20.0%.
  • Genitourinary Drugs Market - The global genitourinary drugs market accounted for USD 28.2 billion in 2015 and is anticipated to grow at a CAGR of over 0.8% during the forecast period. 

Grand View Research has segmented the global thalassemia market based on therapeutic class, pipeline, and region: 

  • Thalassemia Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022) 
    • Iron Chelating Drugs
      • Exjade/Jadenu (deferasirox)
  • Pipeline Outlook (Revenue, USD Million, 2016 - 2022) 
    • Gene Therapy
      • LentiGlobin
  • Regional Outlook (Revenue, USD Million, 2016 - 2022) 
    • U.S.
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Japan

Read Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

SOURCE Grand View Research, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store